Nature Medicine, Published online: 01 April 2026; doi:10.1038/d41591-026-00019-1
After decades of stagnation, a renewed push in tuberculosis research is expanding the drug and vaccine pipeline to bring one of humanity’s oldest and deadliest infectious diseases under control.
Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04322-9
Nourishing people demands collaboration across sectors, political cycles and countries.
Nature Medicine, Published online: 31 March 2026; doi:10.1038/d41591-026-00018-2
In the phase 3 EVOKE(+) trials, semaglutide did not slow clinical progression of Alzheimer’s disease, but the findings provide new insights in the ongoing quest for treatments.
Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04303-y
ProtAIDe-Dx is a deep joint-learning model that uses plasma proteomics to provide simultaneous probabilistic diagnoses across six conditions associated with aging.
Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8
Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.
Nature Medicine, Published online: 30 March 2026; doi:10.1038/s41591-026-04286-w
We have systematically mapped the exposome onto health and disease risk to replace pervasive fragmented research. Although exposure associations are modest, these reproducible patterns reflect how our surroundings can affect our bodies and collectively shape our health. Our atlas provides a blueprint for integrating and evaluating environmental factors into precision medicine.
Nature Medicine, Published online: 30 March 2026; doi:10.1038/s41591-026-04321-w
Despite major global declines in ischemic heart disease mortality, the influence of suboptimal diet remains substantial and unevenly distributed across populations. This study quantifies the contributions of individual dietary components to ischemic heart disease over more than 30 years and uncovers persistent disparities by age, sex, region and socioeconomic status.
Nature Medicine, Published online: 30 March 2026; doi:10.1038/s41591-026-04259-z
Genetic sequencing data from a large cohort of Latin American individuals showed that the genes that are significantly associated with the risk of autism extensively overlapped with those found in genome-wide sequencing studies in people of predominantly European ancestry.
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04296-8
Early clinical data on in vivo CAR-T cell therapy for multiple myeloma reveals key mechanistic insights and could mark the beginning of a new era of fast, streamlined and accessible immunotherapies.
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-025-04115-6
A blueprint to accelerate rare pediatric gene therapy approvals
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04244-6
In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5
Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.
Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04298-6
Local control, remote expertise: governing therapeutic telemedicine in wartime
Nature Medicine, Published online: 24 March 2026; doi:10.1038/d41591-026-00016-4
The small molecule rezatapopt binds a unique pocket in Y220C-mutant p53 and restores its tumor-suppressor function; a phase 1 study provides proof of concept of this therapeutic approach.
Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4
The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.
Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04253-5
In a large UK-based primary care randomized trial, immediate artificial intelligence (AI)-driven prioritization of chest X-rays did not significantly shorten time to computed tomography or lung cancer diagnosis versus standard workflow, suggesting that AI-based prioritization alone is unlikely to accelerate the lung cancer diagnostic pathway.
Nature Medicine, Published online: 16 March 2026; doi:10.1038/d41591-026-00015-5
A ‘universal vaccine’ administered intranasally provided mice broad protection against respiratory bacteria and viruses, paving the way for human studies.
Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04275-z
Artificial intelligence models are evolving from chats to hypotheses. Now their ideas are being validated in organoids and animals — and even in early-stage clinical trials.
Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9
In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.
Nature Medicine, Published online: 13 March 2026; doi:10.1038/s41591-026-04311-y
The field of genetic therapies needs robust investments, transparency and reliable regulatory frameworks to overcome recent challenges and continue to translate new technologies into patients’ benefit.
Login